Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (10)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Vallera, D. A.
Right arrow Articles by Blazar, B. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vallera, D. A.
Right arrow Articles by Blazar, B. R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Protein Engineering, Vol. 12, No. 9, 779-785, September 1999
© 1999 Oxford University Press

Targeting myeloid leukemia with a DT390-mIL-3 fusion immunotoxin: ex vivo and in vivo studies in mice

Daniel A. Vallera1,2, Su-Yeong Seo3, Angela Panoskaltsis-Mortari4, James D. Griffin5 and Bruce R. Blazar4

University of Minnesota Cancer Center, 1 Departments of Therapeutic Radiology (Section on Experimental Cancer Immunology) and 4 Pediatrics, Division of Bone Marrow Transplantation, Minneapolis, MN 55455, USA, 3 Department of Microbiology, College of Medicine,Dong-A University, Pusan, South Korea and 5 Dana-Farber Cancer Institute, Boston, MA, USA

The IL-3 receptor was expressed on a high frequency of myeloid leukemia cells and also on hematopoietic and vascular cells. We previously showed that a recombinant IL-3 fusion immunotoxin (DT390IL-3) expressed by splicing the murine IL-3 gene to a truncated diphtheria toxin (DT390) gene selectively killed IL-3R+ expressing cells and was not uniformly toxic to uncommited BM progenitor cells (Chan,C.-H., Blazar,B.R., Greenfield,L., Kreitman,R.J. and Vallera,D.A., 1996, Blood, 88, 1445–1456). Thus, we explored the feasability of using DT390IL-3 as an anti-leukemia agent. DT390IL-3 was toxic when administered to mice at doses as low as 0.1 µg/day. The dose limiting toxicity appeared to be related to platelet and bleeding effects of the fusion toxin. Because of these effects, DT390IL-3 was studied ex vivo as a means of purging contaminating leukemia cells from BM grafts in a murine autologous BM transplantation. In this setting, as few as 1000 IL-3R-expressing, bcr/abl transformed myeloid 32Dp210 leukemia cells were lethal. An optimal purging interval of 10 nM/l for 8 h eliminated leukemia cells from 32Dp210/BM mixtures given to lethally irradiated (8 Gy) C3H/HeJ syngeneic mice. Mice given treated grafts containing BM and a lethal dose of 32Dp210 cells survived over 100 days while mice given untreated grafts did not survive (P < 0.00001). DT390IL-3 may prove highly useful for ex vivo purging of lethal malignant leukemia cells from autologous BM grafts.

Keywords: bone marrow transplantation/cancer/diphtheria toxin/IL-3/immunotoxin

2 To whom correspondence should be addressed


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Protein Eng Des SelHome page
C. Li, W. A. Hall, N. Jin, D. A. Todhunter, A. Panoskaltsis-Mortari, and D. A. Vallera
Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice
Protein Eng. Des. Sel., May 1, 2002; 15(5): 419 - 427.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Feuring-Buske, A. E. Frankel, R. L. Alexander, B. Gerhard, and D. E. Hogge
A Diphtheria Toxin-Interleukin 3 Fusion Protein Is Cytotoxic to Primitive Acute Myeloid Leukemia Progenitors But Spares Normal Progenitors
Cancer Res., March 1, 2002; 62(6): 1730 - 1736.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.